PBM
Propel Bio Management Portfolio holdings
AUM
$191M
Turnover
36.59%
1-Year Est. Return
102.42%
This Fund
S&P 500
This Quarter
Est. Return
+40.62%
1 Year Est. Return
+102.42%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$191M
AUM Growth
+$32.4M
(+20%)
Cap. Flow
-$2.57M
Cap. Flow
% of AUM
-1.34%
Top 10 Holdings %
Top 10 Hldgs %
68.15%
Holding
41
New
3
Increased
12
Reduced
10
Closed
12
Avg Time Held
0.8
years
Top 10 Avg Time Held
1.1
years
Top 20 Avg Time Held
0.8
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Milestone Pharmaceuticals
MIST
|
+$5.29M |
| 2 |
Artiva Biotherapeutics
ARTV
|
+$5.01M |
| 3 |
SCYNEXIS
SCYX
|
+$3.37M |
| 4 |
Aquestive Therapeutics
AQST
|
+$3.08M |
| 5 |
Palisade Bio
PALI
|
+$2.89M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vor Biopharma
VOR
|
+$5.59M |
| 2 |
Viridian Therapeutics
VRDN
|
+$4.09M |
| 3 |
Oculis Holding
OCS
|
+$3.28M |
| 4 |
Trevi Therapeutics
TRVI
|
+$2.65M |
| 5 |
Coherus Oncology
CHRS
|
+$2.41M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 83.84% |
| 2 | Energy | 16.16% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
26
LeonaBio Inc
LONA
$50.8M
| $1.37M | 0.72% |
149,279
| – | – |
2023 Q4
10 quarters
|
|
27
Maze Therapeutics
MAZE
$1.46B
| $1.31M | 0.68% |
43,798
| – | – |
2026 Q1
1 quarter
|
|
28
Corvus Pharmaceuticals
CRVS
$789M
| $1.05M | 0.55% |
70,380
-15,411
| -18% | -$214K |
2026 Q1
1 quarter
|
|
29
Sagimet Biosciences
SGMT
$535M
| $973K | 0.51% |
+125,878
| New | +$856K |
2026 Q2
0 quarters
|
|
30
Aldeyra Therapeutics
ALDX
$47.7M
| – | – |
-730,606
| Closed | -$1.23M | – |
|
|
31
Coherus Oncology
CHRS
$162M
| – | – |
-1,420,550
| Closed | -$2.41M | – |
|
32
Connect Biopharma Holdings
CNTB
$57.2M
| – | – |
-209,493
| Closed | -$554K | – |
|
33
Nuvation Bio
NUVB
$1.64B
| – | – |
-329,296
| Closed | -$1.41M | – |
|
|
34
Oculis Holding
OCS
$442M
| – | – |
-122,223
| Closed | -$3.28M | – |
|
35
uniQure
QURE
$1.45B
| – | – |
-104,772
| Closed | -$1.71M | – |
|
|
36
Trevi Therapeutics
TRVI
$1.72B
| – | – |
-223,802
| Closed | -$2.65M | – |
|
|
37
Vor Biopharma
VOR
$1.11B
| – | – |
-314,543
| Closed | -$5.59M | – |
|
|
38
Viridian Therapeutics
VRDN
$2.08B
| – | – |
-210,163
| Closed | -$4.09M | – |
|
39
Kalaris Therapeutics
KLRS
$50.7M
| – | – |
-295,771
| Closed | -$1.72M | – |
|
40
Evommune Inc
EVMN
$209M
| – | – |
-55,664
| Closed | -$1.28M | – |
|
41
Satellos Bioscience
MSLE
$141M
| – | – |
-10,145
| Closed | -$57.1K | – |
|
Similar funds
CFG
MWM
ALWM
PFA
NWM
MCA
EMCIP
HPM
Propel Bio Management's Q2 2026 Portfolio in Review
As of Q2 2026, Propel Bio Management held 41 positions worth $191M, up 20% from $159M the previous quarter. Its ten largest holdings account for 68% of the portfolio.
Propel Bio Management's Q2 2026 filing shows 3 new, 12 increased, 10 reduced and 12 closed positions. Its largest new stake was SCYNEXIS: 543,478 shares worth $2.21M. The largest sale was Vor Biopharma, an estimated $5.59M.
By sector, the portfolio is most concentrated in Healthcare at 84% of assets, up from 81% a quarter earlier, followed by Energy.
- Propel Bio Management's largest Q2 2026 buy was SCYNEXIS: 543,478 shares worth $2.21M.
- Propel Bio Management added most to Milestone Pharmaceuticals in Q2 2026, an estimated $5.29M increase.
- Propel Bio Management's biggest Q2 2026 reduction was Abeona Therapeutics, cutting an estimated $1.9M.
- Propel Bio Management fully exited Vor Biopharma in Q2 2026, selling an estimated $5.59M.
- Propel Bio Management's ten largest holdings make up 68% of its $191M portfolio in Q2 2026.
- Propel Bio Management opened 3 new positions and closed 12 in Q2 2026.
- Propel Bio Management's portfolio value rose 20% quarter-over-quarter to $191M.
Based on Propel Bio Management's 13F filing for Q2 2026, filed 13 Aug 2026.